Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29673223 | 1.00 | KMT2A (0.50) | KMT2ARAD52RXFP1CA12CA1 | |
| Hydrochloric Acid SCHEMBL5957935 | 0.98 | KMT2A (0.53) | KMT2ARAD52RXFP1CA12CA1 | |
| SCHEMBL5504129 | 0.98 | KMT2A (0.47) | KMT2ARAD52RXFP1CA12CA1 | |
| Hydrochloric Acid SCHEMBL5957846 | 0.95 | KMT2A (0.50) | KMT2ARAD52RXFP1CA12CA1 | |
| SCHEMBL5957796 | 0.95 | KMT2A (0.46) | KMT2ARAD52RXFP1CA12CA1 | |
| Hydrochloric Acid SCHEMBL6259121 | 0.93 | KMT2A (0.48) | KMT2ARAD52RXFP1TPSAB1ADRA2A | |
| SCHEMBL7862464 | 0.84 | TPSAB1 (0.47) | KMT2ARAD52RXFP1TPSAB1RXRB | |
| SCHEMBL11276885 | 0.83 | KMT2A (0.41) | KMT2ARAD52RXFP1CA12CA1 | |
| SCHEMBL5079011 | 0.83 | TAAR1 (0.45) | CA12CA1CA2CA7CA14 | |
| SCHEMBL30496717 | 0.83 | TAAR1 (0.45) | CA12CA1CA2CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119242040-A | Heat-resistant high-hardness engineering plastic and preparation method thereof | 广州市众拓塑胶模具有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| CN-119242040-A | Heat-resistant high-hardness engineering plastic and preparation method thereof | 广州市众拓塑胶模具有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119242040-A | Heat-resistant high-hardness engineering plastic and preparation method thereof | 广州市众拓塑胶模具有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| US-8524951-B2 | Process for production of hydroxyadamantaneamine | SHIONOGI & CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524951-B2 | Process for production of hydroxyadamantaneamine | SHIONOGI & CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8084646-B2 | Process for production of hydroxyadamantaneamine | SHIONOGI & CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2011-11-03 | — | — | US | disclosed |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | SHIONOGI & CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2088136-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | Shionogi Co., Ltd. (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | KMT2A 4800/4885RAD52 4239/4885RXFP1 170/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | KMT2A 4755/4885RAD52 3741/4885RXFP1 49/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | KMT2A 4800/4885RAD52 4239/4885RXFP1 170/4885 |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | KMT2A 3013/4885RAD52 4448/4885RXFP1 820/4885 |
| US-20100105923-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | KMT2A 2337/4885RAD52 1164/4885RXFP1 3246/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | KMT2A 3013/4885RAD52 4448/4885RXFP1 820/4885 |
| US-20110269971-A1 | PROCESS FOR PRODUCTION OF HYDROXYADAMANTANEAMINE | HAAO, CYP4A11, CYP4F11 | KMT2A 2337/4885RAD52 1164/4885RXFP1 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.